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Abstract
Human Adenovirus Type 4 (HAdV-4) is responsible for epidemic outbreaks of Acute Respiratory Disease (especially in military recruits), and is
known to cause significant morbidity with several reported cases of mortality. However, we do not understand why this serotype causes such high
morbidity, and have little insight into the immunobiology of HAdV-4 infections. We have now developed a replication attenuated HAdV-4 vector
system, and through it, demonstrate that HAdV-4 virions have enhanced infectivity of certain cell types and reveal aspects of the serotype-specific
heightened innate immunogenicity of infectious HAdV-4 capsids both in vitro and in vivo. We further found that elements of this serotype-specific
immunogenicity were dependent upon interactions with the complement system. These findings provide insights into the mechanisms possibly
underlying the known morbidity accompanying wild-type HAdV-4 infections as well as highlight important considerations when considering
development of alternative serotype vectors.
© 2008 Elsevier Inc. All rights reserved.Keywords: Adenovirus; Vectors; Serotype 4; Innate immune response; Complement; Inflammation; Adaptive responseIntroduction
Human Adenovirus Type 4 (HAdV-4) is known to be one of
the predominant serotypes causing Acute Respiratory Disease
(ARD), accounting for 60–80% of ARD affecting military camps
(Hilleman, 1957; Hilleman et al., 1955). This particular ade-
noviral serotype is associated with high rates of morbidity and
has been associated with recruit mortality, prompting the deve-
lopment of a HAdV-4 vaccine (Levin et al., 1967; Top et al.,Abbreviations: Ad, adenovirus; HAdV-4, Human Adenovirus Type 4;
HAdV-5, Human Adenovirus Type 5; dpi, days post-infection; ELISA, Enzyme-
linked Immunosorbance Assay; ELISPOT, Enzyme Linked Immuno-Spot; moi,
multiplicity of infection; Th1, T-helper type 1; LacZ, beta-galactosidase; wpi,
weeks post-infection.
⁎ Corresponding author. 4194 Biomedical and Physical Sciences Bldg,
Michigan State University, East Lansing, MI 48823, USA.
E-mail address: amalfit1@msu.edu (A. Amalfitano).
0042-6822/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2008.01.0171971b,c,a; Russell et al., 2006b; Chanock et al., 1966). While its
virulence has long been recognized, recent studies have also
demonstrated that the transmission of HAdV-4 is more epidemic
than previously appreciated. In one of the few viral transmission
studies to date, evidence of HAdV-4 infection was documented to
increase from 33% of recruits at the beginning of basic training
to ∼97% of recruits by the sixth week of basic training (Russell
et al., 2006a). While these characteristics are considered detri-
mental, it is possible that their utilization in a HAdV-4 based
vector platform may prove to be clinically useful, for example
when utilized in vaccine applications that require heightened
immunogenicity. In this study, we characterize the immunogenic
properties of a first generation HAdV-4 vector, and evaluate its
potential as a tool for viral and clinical research.
Although previous studies have employed partially modified
HAdV-4 viruses obtained by recombination based methods in
mammalian cells (in vivo manipulation), we used a bacterial
454 Z.C. Hartman et al. / Virology 374 (2008) 453–467(in vitro) based method to efficiently engineer an [E1−,E3−]
HAdV-4 based vector bearing reporter transgenes, as has been
done with the more commonly used HAdV-5 serotype (Hsu
et al., 1992; Chengalvala et al., 1991, 1997; Lubeck et al., 1989;
Hodges et al., 2001). In doing so, we are able to directly compare
the infectivity and immunogenicity of these two different viral
serotype based vectors.
Our results demonstrate higher infectivity of the HAdV-4
based vector in certain epithelial cell lines in vitro, as well as
preferential localization to the spleen following intravascular
injection in vivo relative to identical treatments utilizing HAdV-
5 vectors. Our studies also demonstrate an enhanced innate im-
munogenicity of HAdV-4 based vectors that is capsid dependent.
We further determined that the enhanced innate immunogenicity
of HAdV-4 is in part, dependent upon a functional complement
system in vivo, a result paralleling previous findings noted with
use of HAdV-5 vectors. Finally, we found that early innate
immune responses to HAdV-4 do not substantially impact upon
downstream adaptive immune responses to HAdV-4 capsid
proteins, but rather, elicit diminished antibody responses to vec-
tor encoded transgene products. Besides the pragmatic im-
plications of our results relative to the use of alternative serotype
Ad based vectors in general, our results also suggest that the
infectious and immunogenic nature of HAdV-4 is significantly
attributable to its particular capsid composition.
Results
Development of a plasmid based HAdV-4 system
To explore the nature, and exploit the potential of HAdV-4, we
developed a plasmid based system that would allow for the
insertion of multiple gene expression cassettes into the E1 and/
or E3 regions of HAdV-4, thereby generating a replication
incompetent HAdV-4 based vector platform. To achieve this we
employed a plasmid based, bacterial homologous recombination-
approach that has proved successful for the construction of other
Ad serotype vectors (Nilsson et al., 2004).We first constructed the
HAdV-4 genomic “Rescue” shuttle vector, HAdV-4-pShuttle, that
contained both the 5′ and 3′ terminal ends of the HAdV-4
genome. HAdV-4-pShuttle was BamHI linearized and co-
transformed into recombinogenic Escherichia coli BJ5183 cells
along with purified wild-type HAdV-4 genomic DNA. A
kanamycin resistant clone containing the HAdV-4 genomic
sequence (pHAdV-4) was obtained and the HAdV-4 RI-67
identity of this clone was confirmed by multiple restriction
enzyme digests and a 1× sequence of the entire plasmid (data not
shown). The left and right ITR elements of the HAdV-4 genome,
present in pHAdV-4, were separated from the bacterial origin and
kanamycin resistance genes (contained in pHAdV-4) with I-SceI.
Transfection of the I-SceI digested plasmid resulted in onset of
typical Ad cytopathic effects in 293 cells, confirming integrity of
the total HAdV-4 genomic construct.
We simultaneously constructed a shuttling plasmid, pHAdV-
4[E1−], for the rapid mobilization of desired genetic sequences
into the E1 region of the HAdV-4 genome, rendering the HAdV-
4 vector replication incompetent unless grown on E1 transcom-plementing cell lines (see Supplementary Fig. 1). A second
shuttle plasmid, pHAdV-4[E3−], was also constructed to faci-
litate “shuttling” of genes into the E3 region (see Supplementary
Fig. 1). [E1−,E3+] and [E1−,E3−]HAdV-4 plasmids with and
without transgene insertions were I-SceI digested and trans-
fected into 293 cells, where all viruses were successfully grown
to high titer, as has been demonstrated for related Simian Group
E Ad vectors (Farina et al., 2001). Integrity of the HAdV-4
genomes contained within the CsCl2 purified vectors was
confirmed by subsequent sequencing and restriction enzyme
digest based mapping. Of note, all HAdV-4 vector preparations
tested negative for any detectable RCA (Replication Competent
Adenovirus, or E1+ adenovirus), likely owing to the significant
sequence difference between HAdV-4 E1a and E1b gene
sequences and the Ad5 derived E1a and E1b sequences present
in human 293 cells. Finally, silver staining of CsCl2 purified
HAdV-4 vectors revealed them to have equivalent protein
content per equivalent numbers of viral capsids (based upon
SDS disruption and OD260 method for viral particle number
determination) in comparison to similarly assessed HAdV-5
based vectors (data not shown).
Differential HAdV-4 infectivity in vitro
Previous investigations using wild-type HAdV-4 in tissue
culture systems, as well as high hospitalization rates accom-
panying natural HAdV-4 infection, suggest fundamental differ-
ences exist between these two serotypes that may impact both its
infectivity and immunogenicity (Zhang et al., 2003; Mei et al.,
2002; Chengalvala et al., 1997; Russell et al., 2006a). To
formally test for these differences, we infected several cell lines
with equal particle numbers of [E1−,E3−] HAdV-4 or HAdV-5
vectors, both expressing an identical LacZ reporter transgene
driven by a CMV enhancer/promoter element (Figs. 1A–F).
Using LacZ activity as a determinant of cellular transduction, we
found that both vectors transduced human embryonic kidney
293 cells and liver derived Hep3B cells equally well. However,
although the differences were modest, these analyses revealed
that HAdV-4 more efficiently transduced human lung epithelial
A549 cells, HepG2, and HeLa cells than did HAdV-5. Con-
versely, the HAdV-5 based vector was significantly more
efficient at transducing RAW264.7 mouse macrophages. To
more accurately assess the infectivity of these viruses, we used
real-time PCR to amplify, and quantify CMV promoter se-
quences (contained in both vectors) present within the infected
cells. Using this assay, we confirmed the transduction effi-
ciencies observed in HeLa, HepG2 and Hep3B cells, however,
we found comparable numbers of either vector genomes present
within RAW264.7 cells (Fig. 1G). A recent study concluded that
vector induced interferon responses could repress the CMV
promoter, the same promoter used to drive the LacZ transgene in
our vector constructs (Hensley et al., 2007). To assess this, we
evaluated interferon-beta production following RAW264.7
infection by either HAdV-4 or HAdV-5 vectors (Fig. 2). At
24 hpi, we found that only intact and not heat disrupted HAdV-4
vectors induced significantly greater levels of IFN-β, suggesting
that interferon mediated promoter repression may be responsible
Fig. 1. Comparison of HAdV-5 and HAdV-4 vector infectivity and uptake in vitro. (A–F) Cells were plated at equal densities and infected with equivalent particle numbers
of LacZ expressing [E1−,E3−]HAdV-4 (left panel) and HAdV-5 (right panel) vectors. Two hundred ninety three cells were infected with 300 vp/cell, Hep3B with 3000 vp/
cell, A549 with 3000 vp/cell, HepG2 with 3000 vp/cell, HeLa with 3000 vp/cell, and RAW264.7 with 30,000 vp/cell. At 24 h post-infection (hpi), cells were fixed and
stained using X-Gal to visualize the presence of β-galactosidase, as described in Materials and methods. The graphs depict the data obtained from replicate wells that were
equivalently infected, but were also lysed and assayed forβ-galactosidase activity at 24 hpi as described inMaterials andmethods. An “⁎” or “⁎⁎” indicatesβ-galactosidase
activity levels were significantly different ( pb0.05 or pb0.01 respectively) between Ad infected cells and mock infected cells while “# ” or “## ” indicatesβ-galactosidase
activity levels were significantly different ( pb0.05 or pb0.01 respectively) between HAdV-4 and HAdV-5 infected cells. (G) Relative quantitative measure of RAW264.7
cells transduced HAdV-4 genomes in comparison to HAdV-5 genomes. HAdV-4 and HAdV-5 were infected with equal particle number of HAdV-4 and HAdV-5 as
described in A–F and DNA extracted from cells at 24 hpi and assessed for genome copy number by real-time PCR. Data is shown as HAdV-4 genomes per 1 HAdV-5
genome where “# ” or “## ” indicates genome copy number differences that were significant different ( pb0.05 or pb0.01 respectively) between HAdV-4 and HAdV-5
infected cells. Error bars are indicative of standard deviations. In all experiments N=3 or 4 and error bars are indicative of standard deviations.
455Z.C. Hartman et al. / Virology 374 (2008) 453–467for reduced LacZ expression by the HAdV-4 capsid. These
results offered initial evidence for the heightened immunogeni-
city of HAdV-4 vectors compared to HAdV-5 and led us to more
fully explore these two vectors in macrophages, a cell type that
figures prominently in the innate immune response to adeno-
virus in multiple contexts.Enhanced HAdV-4 immunogenicity in vitro
To further evaluate the relative immunogenicities of both viral
vectors, we exposed RAW264.7 cells to HAdV-4 or HAdV-5
vectors at a dose of 30,000 viral particles per cell and sub-
sequently assessed the production of multiple cytokines and
Fig. 2. HAdV-4 vectors induce significantly greater IFN-β responses in comparison
toHAdV-5 vectors in vitro. Equal numbers of RAW264.7macrophageswere infected
with [E1−,E3−]LacZ HAdV-4 and HAdV-5 vectors (either intact, after UV irra-
diation, or heat treatment at 56 °C) at 3000 vp/cell. Supernatants were collected and
measured for IFN-β concentration at 24 hpi. In all experiments N=3 and error bars
indicate standard deviations.An “⁎”or “⁎⁎” indicates those time pointswhen levels of
the respective cytokine/chemokine were significantly different (pb0.05 or pb0.01
respectively) betweenAd infected andmock infected cells and “# ” or “##” indicates
those time points when levels of cytokine/chemokine were significantly different
(pb0.05 or pb0.01 respectively) between HAdV-4 and HAdV-5 counterparts.
456 Z.C. Hartman et al. / Virology 374 (2008) 453–467chemokines at 6 h post-infection (Fig. 3). At this time point, the
HAdV-4 based vector induced significantly higher levels of
RANTES, Eotaxin, TNF-α, MCP-1, MIP-1α, and MIP-1βFig. 3. Significantly elevated cytokine/chemokine response to HAdV-4 vectors in co
numbers of macrophages were infected with [E1−,E3−]LacZ HAdV-4 and HAdV-5
supernatant was collected and measured at 6 hpi for all cytokines. Three experiment
deviations. An “⁎” or “⁎⁎” indicates those time points when levels of the respective cy
between Ad injected and mock infected cells and “# ” or “ ## ” indicates those time po
pb0.01 respectively) between HAdV-4 and HAdV-5 infected cells.relative to the HAdV-5-based vector. At lower particle titers
(3000 vp/cell) only HAdV-4 based vectors demonstrated detect-
able immunogenicity, inducing significant levels of MIP-1α,
MIP-1β, RANTES, and TNF-α. To assess the possibility that
these disparate immune responses were due to differences in
expression of virally encoded gene products, both serotypes were
UV-inactivated (to eliminate both viral replication and gene tran-
scription) before macrophage infection. As before, HAdV-4 UV-
inactivated vectors elicited greater cytokine and chemokine res-
ponses compared to UV-inactivated HAdV-5 based counterparts
(Fig. 3). To test if HAdV-4 DNA was innately more immunos-
timulatory than HAdV-5 DNA, RAW264.7 macrophages were
transfected with vector DNA purified from each virus, and cyto-
kine production was assessed 24 h post-transfection (Supple-
mentary Fig. 2). HAdV-4 DNA proved no more stimulatory than
HAdV-5 DNA for any cytokine tested (Fig. 4).
To confirm that the dependence of the differential immunos-
timulatory nature of HAdV-4 andHAdV-5 vectors was predicated
on intact and infectious virions, we again subjected them tomparison to HAdV-5 vectors by the RAW264.7 murine macrophage line. Equal
vectors at either a high dose (30,000 vp/cell) or a low dose (3000 vp/cell) and
al replicates were performed for all groups (N=3). Error bars indicate standard
tokine/chemokine were significantly different ( pb0.05 or pb0.01 respectively)
ints when levels of cytokine/chemokine were significantly different ( pb0.05 or
Fig. 4. Equivalent immunogenic response to HAdV-4 and HAdV-5 vector genomes after transfection into RAW264.7 cells. Equal numbers of macrophages were
transfected with equal quantities of HAdV-4 or HAdV-5 vector DNA and supernatants harvested at 24 hpi and assessed for cytokine and chemokine production as
described in Materials and methods. Three experimental replicates were performed for all groups (N=3). Error bars indicate standard deviations. An “⁎” or “⁎⁎”
indicates that levels of the respective cytokine/chemokine were significantly different ( pb0.05 or pb0.01 respectively) between Ad transfected and mock transfected
cells. No significant differences were observed between HAdV-4 and HAdV-5 transfected cells.
Fig. 5. Biodistribution of intravenously injected HAdV-4 vectors in comparison to HAdV-5 vectors in mice. (A) In situ staining of β-galactosidase activity in liver
sections ofmice injectedwith 5×1010 particles of HAdV-5LacZ or HAdV-4LacZ. Three representative experimental animals are shown for each vector. (B) Quantitative
measure of β-galactosidase activity in liver after i.v. injection of 5×1010 particles of HAdV-5LacZ or HAdV-4LacZ vector. N=11 for HAdV-5 injected mice and N=3
for HAdV-4 and mock injected mice. An “⁎” or “⁎⁎” indicates that liver LacZ activity was significantly greater ( pb0.05 or pb0.01 respectively) than activity levels
observed in mock infected counterparts (C) Real-Time PCR assessment of Ad genome copies per GAPDH copies in multiple organs. N=3 for both vector for all organs
assayed with the exception of liver where N=11 for HAdV-5 injected mice and N=6 for HAdV-4 injected mice at both titers. A “# ” or “ ## ” indicates significant
differences in Ad DNA copies per cell in comparison of mice identically treated with HAdV-4 or HAdV-5 vectors ( pb0.05 or pb0.01 respectively). Error bars in all
figures indicate standard deviations.
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Fig. 6. Significantly elevated plasma cytokine/chemokine concentrations in HAdV-4 infected mice compared to HAdV-5 infected mice. Plasma levels of each of the indicated cytokines or chemokines were measured in
the plasma derived from the respectively treated groups of mice as described in Materials and methods. Error bars indicate standard deviations. An “⁎” or “⁎⁎” indicates those time points when levels of the respective
cytokine/chemokine were significantly different ( pb0.05 or pb0.01 respectively) between Ad injected and mock injected mice and “# ” or “## ” indicates those time points when levels of cytokine/chemokine were
significantly different ( pb0.05 or pb0.01 respectively) between HAdV-4 injected C57BL/6 mice and either HAdV-5 injected C57BL/6 or HAdV-4 injected C3KO mice counterparts. N=4, 3, and 4 for mock injected
mice at 1, 6, and 24 hpi time points respectively;N=7, 9, and 6 at the respective 1, 6, and 24 hpi time points for HAdV-4 injected C57BL/6 mice (all time points). N=4, 5, and 3 at 1, 6, and 24 hpi respectively for HAdV-5















459Z.C. Hartman et al. / Virology 374 (2008) 453–467various heat treatments prior to macrophage infection (Fig. 3). In
this case, cytokine and chemokine inductions were almost
completely eliminated for both serotypes. In summary, these
results offer indirect evidence that the virion itself, as a three
dimensional structure, is the primary determinant of the
differential immunogenicity between these two vectors.
Biodistribution of HAdV-4 serotype in vivo
Since HAdV-4 possesses a shorter fiber compared to HAdV-5
(12 and 22 β-repeats respectively), and lack Heparan Sulfate
Proteoglycan (HSPG) motifs in their fibers (yet do bind to CAR
in vitro), we assessed whether these vectors could successfully
transduce the murine liver (Shayakhmetov and Lieber, 2000; Ni
et al., 2005). While injection of 5×1010 adenoviral particles did
not result in complete liver transduction, both quantitative and
qualitative assessments of liver derived LacZ expression revea-
led that HAdV-5 LacZ transduced the liver more efficiently than
did the HAdV-4 based vectors (Figs. 5A and B). Using a quan-
titative PCR approach, we corroborated transduction findings in
the liver, and further assessed differences in overall vector
biodistribution (Figs. 5A and B). This analysis revealed baseline
uptake of either virus in the heart, lung, kidney and bonemarrow.
However, levels of HAdV-4 genomes in the spleen were sig-
nificantly higher than levels of HAdV-5 genomes. In fact, injec-
tion of 5-fold less HAdV-4 virus (1×1010 vp/mouse) still resulted
in splenic HAdV-4 vector genome levels equivalent to mice in-
jected with HAdV-5 virus at a higher dose of 5×1010 vp/mouse
(Fig. 5C).Fig. 7. HAdV-4 vectors induce a more significant thrombocytopenia upon
intravenous administration in comparison to HAdV-5 counterparts. Platelet
enumerations were performed in the indicated groups of control or virus injected
mice as described in Materials and methods. All mice were on the C57BL/6
background, including the C3KO group of mice. Error bars indicate standard
deviations. An “⁎” or “⁎⁎” indicates those time points when platelet levels are
significantly different ( pb0.05 or pb0.01 respectively) between Ad injected
and mock injected mice and “ # ” or “ ## ” indicates those time points when
platelet concentrations were significantly different ( pb0.05 or pb0.01
respectively) between HAdV-4 injected C57BL/6 mice and either HAdV-5
injected C57BL/6 or HAdV-4 injected C3KO mice counterparts. N=3 for mock
injected mice and N=5 for HAdV-5 injected mice. For HAdV-4 injected mice,
N=7 for mice injected with 5×1010 particles, N=5 for mice injected with
1×1010 particles and N=7 for C3KO mice injected with 5×1010 particles.HAdV-4 vectors promote increased pro-inflammatory cytokine
and chemokine responses in vivo
To determine differences in innate immunogenicity in vivo, we
initially injectedmice with either HAdV-4 or HAdV-5 vectors at a
dose of 1.5×1011 particles per animal, a dose we have previously
used to evaluate innate responses to HAdV-5 based vectors
(Hartman et al., 2007; Kiang et al., 2006b). However, at this dose
HAdV-4 injected animals rapidly progressed to a moribund state
(within 20min of injection) and could not be fully evaluated. Thus
we proceeded with experiments at vector doses of 5×1010
particles per mouse, and collected serum at 1, 6, and 24 hpi to
assess the resulting induction of plasma cytokines and chemo-
kines (Fig. 6). Although both vectors induced relatively similar
levels of IL-12(p40) at all tested time points, we found that the
HAdV-4 vector induced significantly higher levels of several pro-
inflammatory cytokines and chemokines relative to the HAdV-5
vector, inclusive of IL-6, G-CSF,MIP-1β, MCP-1, and RANTES
at 6 hpi and G-CSF and RANTES at 24 hpi. Thus, relative to
HAdV-5 vectors, HAdV-4 vectors elicited a more pronounced
inflammatory cytokine and chemokine profile in vivo, mirroring
many of the in vitro differences observed after exposure of
macrophages to either vector.
HAdV-4 vector enhanced induction of thrombocytopenia in vivo
HAdV-5 vectors induce thrombocytopenia in a variety of
species including humans (Morral et al., 2002; Toietta et al.,
2005; O'Neal et al., 1998; Cichon et al., 1999; Raper et al.,
2002). Based on the cytokine/chemokine profile differences we
noted between HAdV-5 and HAdV-4 vectors in vivo, we sought
to determine if similar, serotype-specific differences in Ad-
initiated thrombocytopenia also exist (Fig. 7). Measures of
thrombocytopenia from Ad injected animals at 24 hpi revealed a
significantly greater level of thrombocytopenia in HAdV-4
injected animals relative to HAdV-5 injected animals at iden-
tical doses. Furthermore, injection of a half-log lower dose of
HAdV-4 LacZ virus (1×1010 particles) resulted in thrombocy-
topenia similar to that observed in mice injected with the higher
dose of HAdV-5 LacZ.
The role of complement in HAdV-4 thrombocytopenia and
inflammatory response
We previously determined that HAdV5-based vector indu-
ced thrombocytopenia is dependent on the presence of an intact
complement system (Kiang et al., 2006b). Furthermore, our
previous in vitro investigations revealed that both HAdV-5 and
HAdV-4 particles bound to complement and activated the
alternative complement pathway in vitro in a capsid-dependent
manner (Jiang et al., 2004). Thus, we sought to determine
whether complement was involved in HAdV-4 mediated throm-
bocytopenia and inflammatory cytokine responses. To assess
this, we injected complement deficient mice (C3-KO) with
5×1010 particles of HAdV-4 LacZ virus and measured throm-
bocytopenia at 24 hpi. Blood platelet levels in C3KO HAdV-4
injected mice were significantly higher than levels observed in
460 Z.C. Hartman et al. / Virology 374 (2008) 453–467their HAdV-4 injected C57BL/6 counterparts and were also
not significantly different from levels in mock injected mice
(Fig. 7). Thus, in accord with previously published observations
made following HAdV-5 LacZ injection, an intact complement
system mediates Ad-induced thrombocytopenia in response to
intravenous injection of HAdV-4.
We have previously shown that the full elaboration of cyto-
kines induced following systemic HAdV-5 injection is dependent
on a functional complement system (Kiang et al., 2006a). To
evaluate whether complement was similarly required for the
induction of inflammatory cytokines in response to HAdV-4, we
intravenously injected either HAdV-4 orHAdV-5 based vectors at
a dose of 5×1010 vp/mouse into complement deficient animals
(Fig. 6). At this viral dose, the requirement of complement in the
elaboration of HAdV-5 induced cytokines was largely recapitu-
lated in comparison to previously published data. In a similar
fashion, we also found that the induction of IL-6, MCP-1, and
MIP-1β following HAdV-4 injection was, in part, dependent ona functional complement system.However, in contrast toHAdV-5
injected complement deficient animals, the HAdV-4 mediated
induction of IL-12(p40), G-CSF, and RANTES was not com-
plement dependent (Fig. 6). Thus, while complement plays a
significant role in enhancing the HAdV-5 and HAdV-4 induction
of certain inflammatory cytokines/chemokines, the levels and or
type of dependence is serotype-specific.
Adaptive immune responses to HAdV-4 and HAdV-5 vectors
The innate response to a pathogen can significantly impact
upon the resulting adaptive immune response to the same patho-
gen. Therefore, we next sought to determine whether differences
in the innate immune responses that we noted between the twoAd
serotype vectors would translate into altered adaptive immune
responses. To address this question, mice were injected either
intravenously or in the footpad with 5×1010 particles of HAdV-4
or HAdV-5 vectors expressing LacZ, and were tested at 2 weeks
post-injection (wpi) for transgene-specific IgG antibody res-
ponses (Figs. 8A and B). Interestingly, we found that HAdV-5
vectors induced significantly more IgG antibodies to the encoded
LacZ transgene compared to HAdV-4 injected counterparts, a
result that was replicated independent of the route of virus
administration. Since IL-6 and other cytokines can skew Th1/Th2
differentiation, we sought to determine whether these serotype-
specific differences in antibody induction were simply limited to
the Th1 IgG class (Diehl et al., 2000; Diehl and Rincon, 2002). To
ascertain Th2 responses, we investigated the induction of Th2 IgE
transgene-specific antibodies at 2 wpi (Supplementary Fig. 3). As
with IgG, we found that the levels of LacZ-specific IgE were
significantly greater in HAdV-5-injected animals as compared to
HAdV-4 injected animals. We also confirmed that this response
was not due to a generalized alteration of the murine immuneFig. 8. Diminished transgene-specific IgG responses (but unaffected CTL
transgene-specific responses) in HAdV-4 vector injected mice in comparison to
HAdV-5 vector injected mice. Serum from immunized mice (all 14 days post
respective Ad vector injection) was quantified for anti-LacZ or anti-Ad antibodies
using LacZ and Ad specific ELISA assays as described in Materials and methods.
Data are shown as absorbance values at appropriate serum dilutions, see Materials
and methods for full details. (A) Anti-LacZ IgG antibody ELISA after intravenous
administration of Ad vectors. For HAdV-5 injected mice, N=5 and 4 for mice
treated with 1×1010 and 5×1010 particles respectively. For HAdV-4 injected mice,
N=5 and 3 for mice treated with 1×1010 and 5×1010 particles respectively. N=4
formock injectedmice. (B) Anti-LacZ IgG antibody ELISA after footpad injection
of Ad vectors. N=4, 5, and 4 for the respective HAdV-4 injected group, HAdV-5
injected group and mock injected group. (C) Anti-Ad serotype-specific IgG anti-
body ELISA. IgG antibodies were assessed to serotype-specific capsids using
conditions and replicates described in (A) and (B). (D and E) Day-14 LacZ specific
ELISpot-IFN-γ responses of C57BL/6 mice after footpad injection (D) or intra-
venous injection (E) of HAdV-4LacZ, HAdV-5LacZ, or control vehicle. Sple-
nocytes derived from the respectively treatedmice (14 days postAd injection) were
cultured and exposed to the respective antigens (antigen-specific LacZ protein or
non-specific glucosidase) as described in Materials and methods. For all D and E
groups, N=5 and error bars are indicative of standard deviation. An “⁎” or “⁎⁎”
indicates the levels of the respective IgG antibody was significantly different
( pb0.05 or pb0.01 respectively) betweenAd injected andmock injectedmice and
“# ” or “## ” indicates those time points when the IgG antibody concentration was
significantly different ( pb0.05 or pb0.01 respectively) between Ad injected
between HAdV-4 or HAdV-5 injected groups.
Fig. 9. Significantly elevated IFN-β response to HAdV-4 vectors in comparison
to HAdV-5 vectors after intravenous injection in vivo. Plasma levels of injected
mice were measured for IFN-β by ELISA in the respectively treated groups of
mice as described in Materials and methods. For HAdV-5 injected mice, N=5
and 4 for mice treated with 1×1010 and 5×1010 particles respectively. For
HAdV-4 injected mice, N=5 and 3 for mice treated with 1×1010 and 5×1010
particles respectively. The N=4 for mock injected mice. Error bars indicate
standard deviations. An “⁎” or “⁎⁎” indicates those time points when levels of
the respective cytokine/chemokine were significantly different ( pb0.05 or
pb0.01 respectively) between Ad injected and mock injected mice and “# ” or
“## ” indicates those time points when levels of cytokine/chemokine were
significantly different ( pb0.05 or pb0.01 respectively) between HAdV-4 and
HAdV-5 counterparts.
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ficant IgG responses to their respective capsids (Fig. 8C).
It is possible that HAdV-4 enhanced type I interferon res-
ponses observed in vitro also occur in vivo leading to the
repression of LacZ transgene expression and thus serotype-
specific, diminished anti-LacZ antibody responses. As we found
in vitro, the HAdV-4 based vector elicited significantly greater
plasma levels of IFN-β relative to the HAdV-5 vector (Fig. 9),
potentially explaining the diminished IgG and IgE antibody
responses to LacZ observed in HAdV-4 vector treated mice.
We next sought to assess if T-cell responses to the encoded
transgene (LacZ) also differed between vectors. Two weeks after
footpad injection of 5×1010 vp of HAdV-4 or HAdV-5 LacZ
particles, LacZ specific T-cell responses were measured using an
ELISPOT assay. As shown in Fig. 8D, the number of transgene-
specific IFNγ producing T-cells was similar between the two
vector platforms. Similar results were also obtained when lower
doses of vector were injected intravenously (Fig. 8E). Thus,
despite diminished anti-LacZ antibody responses relative to
HAdV-5, HAdV-4 based vectors were capable of inducing sig-Fig. 10. HAdV-4 vectors induce significantly elevated cytokine secretion compared
healthy human donors were prepared as described in Materials and methods. DCs wer
Supernatants were collected and measured at 24 hpi for all cytokines. Three experime
deviations. An “⁎” or “⁎⁎” indicates those time points when levels of the respective cy
between Ad injected and mock treated cells and “# ” or “## ” indicates those time po
pb0.01 respectively) between HAdV-4 and HAdV-5 infected cells.nificant transgene-specific T-cell responses equivalent to that of
HAdV-5 based vectors.
HAdV-4 vectors elicit enhanced pro-inflammatory cytokines/
chemokines compared to HAdV-5 vector in human primary
dendritic cells
Wewished to determine if the differences between theHAdV-4
and HAdV-5 based vectors noted in murine systems could be
detected in human derived immune cells. To address this, we
infected human PBMC derived dendritic cells with 50,000 vp/cell
of either HAdV-4 or HAdV-5 LacZ vectors. At 24 hpi, super-
natants were harvested and cytokine/chemokine secretion was
assessed (Fig. 10). At this time point, the HAdV-4 based vector
induced significantly higher levels of IP-10 (CXCL10), MCP-1,
and RANTES relative to the HAdV-5-based vector. These results
mirror our previous findings using murine cells, and suggest that
the significantly altered immunogenicity of HAdV-4 relative to
HAdV-5 can also be demonstrated in human cells.
Discussion
Human Ad Type 4 is the sole member of the human Group E
adenoviruses, and possesses several interesting etiologic fea-
tures; being responsible for periodic epidemic outbreaks of
infection in military populations, causing high rates of morbi-
dity, and occasional cases of mortality (Russell et al., 2006a,b;
Hilleman, 1957; Gray et al., 2000). These features suggest that
HAdV-4 virions may possess differential infective abilities and
higher immunogenicity relative to other related Ad serotypes.
In this study, we created an [E1−,E3−] replication defective
HAdV-4 platform to investigate its properties relative to the
commonly used [E1−,E3−] replication defective HAdV-5 based
vector. It is becoming increasingly clear that use of alternative
serotype vectors may be useful not only in the context of avoi-
ding pre-existing immunity to a respective vector serotype (e.g.
HAdV-5) but that altered serotypes of vectors may also offer
improved efficacy or safety for particular usages. HAdV-4 vectors
are being evaluated for use as a vector in multiple vaccine efforts
including HIV. In vitro, we found that HAdV-4 vectors displayed
enhanced infectivity in several cell types and elicited greater
immunogenic responses in murine macrophages, the latter result
being dependent upon exposure to intact HAdV-4 capsids. In ato HAdV-5 vectors in human dendritic cells. Primary dendritic cells (DCs) from
e infected with 50,000 vp/cell of [E1−,E3−]LacZ HAdV-4 and HAdV-5 vectors.
ntal replicates were performed for all groups (N=3). Error bars indicate standard
tokine/chemokine were significantly different ( pb0.05 or pb0.01 respectively)
ints when levels of cytokine/chemokine were significantly different ( pb0.05 or
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a HAdV-4 vector displayed altered tissue biodistributions, and
induced a heightened, partially complement dependent, innate
immune response characterized by a higher induction of inflam-
matory cytokines and a more dramatic stimulation of thrombo-
cytopenia on a per particle basis. However, we found that the
heightened innate inflammatory nature of the HAdV-4 vector had
only minor effects on subsequent adaptive responses, primarily
limited to antibody responses to the transgene encoded by the
HAdV-4 vector.
Specifically, we found that HAdV-4 LacZ more efficiently
infected HeLa and HepG2 cells compared to HAdV-5. These
results corroborate and expand upon previous studies that have
detailed an enhanced ability of wild-type HAdV-4 to bind and
infect certain cell types in comparison to wild-type HAdV-5
(Zhang et al., 2003; Mei et al., 2002). However, we noted that
exposure of RAW264.7 murine macrophages to HAdV-4 or
HAdV-5 revealed comparable levels of vector genomic DNA
content but reduced capabilities of the HAdV-4 vector to drive
expression of a CMVenhancer dependent transgene (LacZ). We
also found that HAdV-4 vectors induced significantly greater
secretion of multiple cytokines, including IFN-β, when directly
compared to HAdV-5 vectors. This may offer a possible expla-
nation for the decreased CMV-driven gene expression noted from
the HAdV-4 vector in murine macrophages, since similar results
have been confirmed in IFN-receptor KO mice infected with a
similar immunostimulatory Ad serotype(Hensley et al., 2007).
Our studies also revealed that cytokine and chemokine in-
ductions by the Ads were dependent on intact/infectious virions
and were independent of viral genome transcription (for ex-
ample, when UV-inactivated vectors were utilized). We also
found that transfection of DNA derived from either HAdV-4 or
HAdV-5 based vectors resulted in equivalent immune responses,
suggesting that DNA-dependent effects were not primarily res-
ponsible for the differences in immunogenicity we noted bet-
ween these serotypes in vitro. While some of the HAdV-4
induced cytokines (IL-6 and TNF-α) were broad spectrum in-
flammatory cytokines, other cytokines induced by HAdV-4,
such asMIP-1α, MIP-1β, and RANTES, have been grouped and
classified as ‘type 1’ cytokines, which function together in the
effector phase of macrophage activation (Dorner et al., 2002).
This cytokine profile suggests that the HAdV-4 vector may
enable more vigorous macrophage activation, possibly contri-
buting to the enhanced morbidity noted during HAdV-4 infections.
In vivo assessments of immunogenicity revealed HAdV-4
vectors to be more immunogenic compared to HAdV-5 at early
time points. For example, high dose HAdV-4 injection resulted
in significant morbidity and thus did not allow for complete
evaluation. However, lower dose injections of HAdV-4 vectors
were tolerated and could be compared to lower dose HAdV-5
vector injections. We also observed decreased hepatocyte trans-
duction by HAdV-4-based vectors, possibly due to its short fiber
and lack of a HSPG binding motif (Shayakhmetov and Lieber,
2000; Ni et al., 2005). Interestingly, the spleen was found to
contain more HAdV-4 genomic content then HAdV-5 at 24 hpi,
which may be indicative of more active phagocytosis by diffe-
rent types of sentinel immune cells in vivo.In agreement with results obtained in vitro, we also noted that
HAdV-4 vectors triggered a profound inflammatory response
in vivo, characterized by significantly higher cytokine, chemo-
kine, and IFN-β secretion compared to HAdV-5 vectors. This
HAdV-4 inflammatory response was also accompanied by a
higher propensity to initiate thrombocytopenia relative to HAdV-
5 based vectors.
We have previously shown that HAdV-4 capsids can bind
and activate complement in vitro (Jiang et al., 2004); in this report
we show that several HAdV-4 induced immune responses are
also complement dependent in vivo. For example, complement
deficient mice injected with HAdV-4 vectors had diminished
inflammatory cytokine plasma levels as well as a significantly
diminished ability to induce thrombocytopenia as compared to
HAdV-4 injected wild-type mice. These results were similar to
those previously noted with HAdV-5 vectors, thus demonstrating
the importance of the complement system in the initiation of
several serotype independentAd-induced inflammatory responses
(Kiang et al., 2006b). These observations should heighten scrutiny
when one considers utilization of alternative serotype Ad vectors
in general, as we have recently shown that each serotype has a
unique, innate immune response profile that must be fully
delineated prior to clinical use (Appledorn et al., in press).
Surprisingly, the more pro-inflammatory HAdV-4 capsid
vector did not result in improved adaptive immune responses
to the LacZ transgene, as compared to a “less inflammatory”
HAdV-5 based vector expressing LacZ, a result previously
noted and demonstrated to be mediated by heightened
interferon responses (Hensley et al., 2007). It is possible
that the low level of liver transduction observed following
HAdV-4 LacZ injection resulted in reduced expression of
the LacZ transgene and a subsequently lower anti-LacZ IgG
response. However, it was also noted that HAdV-4 elicited
diminished LacZ specific IgG responses compared to HAdV-5
after footpad injection. Since footpad injections do not result
in high levels of liver transduction, it is unlikely that the
differences in LacZ expression in the liver contributed to the
reduced LacZ specific IgG responses, and that this response
may be more reflective of inherent differences in the innate
immune responses elicited by the serotypes specific capsids
themselves.
Finally, this study also demonstrates enhanced secretion of
multiple inflammatory cytokines following HAdV-4 infection
of human dendritic cells, in a manner qualitatively similar to
findings we noted in murine systems. This result suggests that
intrinsic differences in the capsid structure of HAdV-4 can
impact significantly upon numerous pro-inflammatory path-
ways in human cells, and may thus partially explain the high
morbidity noted in humans upon infection with wild-type
HAdV-4 and potentially other adenoviral serotypes.
In summary, our study provides a new tool for basic and
clinical researchers, and reveals important insights into the in-
fectious nature and immunogenicity of HAdV-4 relative to
HAdV-5 based vectors. More importantly, the utilization of alter-
native serotype gene transfer vectors can alter important aspects of
a respective vector class' biology in ways that may not always be
predictable. Thus, utilization of alternative serotype vectors to
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respective serotype vector) or to improve efficacy (i.e.: improved
usage as a vaccine platform) may also introduce new limitations.
Materials and methods
Construction of HAdV-4 genomic plasmid
Wild-type Adenovirus Type 4 was purchased from ATCC
(strain RI-67, ATCC catalog #1081) and grown on 293 cells using
standard infectious procedures. Virus was purified using a CsCl
double-banding procedure and Viral DNA extracted using phenol
chloroform based procedures. A primer designed to the Ade-
novirus Type 4 fiber was generated (AACCCAAGCTTCTTAC-
TATAACTCTT) and was used to initially confirm the sequence
identity of the resulting virus. Restriction digest mapping analysis
using BstXI, XbaI, XhoI, and BamHI, confirmed the serotype
identity of the resulting virus based on portions of the known
HAdV-4 sequence present in the literature at that time.
Since, much of the HAdV-4 sequence was unknown at this
point, large scale directional sequencing using directional primers
was conducted to span the unknown portions of the Adenovirus
Type 4 genome and was completed with 1× coverage (Duke
HAdV-4 sequence available upon request). When a published
HAdV-4 sequence became available in February of 2005 (Gen-
bank # AY594253) comparison between the two genomes re-
vealed no detectable difference and thus provided additional
verification of serotype identity.
To obtain an HAdV-4 genomic plasmid an “HAdV-4 rescue
shuttle”was built by cloning the terminal “left arm” of the linear








fragments were cloned into pCR2.1-TOPO cloning vectors, then
cut with BamHI and I-SceI and these two fragments were di-
rectionally ligated with a kanamycin resistance-bacterial origin
containing DNA fragment also flanked with I-SceI sites.
Restriction digests and sequencing confirm the sequence iden-
tity and correct orientation of the resulting clones, denoted as
pHAdV-4[E1+] shuttle. This plasmid was linearized by digest-
ing with BamHI and co-transformed along with HAdV-4
genomic DNA into BJ5183 bacteria cells. Kanamycin-resistant
clones were tested by PCR screen and resultant “Wild-
type HAdV-4” clones were grown in Stbl2 cells (Gibco, La
Jolla, CA).
Construction of HAdV-4 vector plasmid shuttle system
To create a HAdV-4 based, [E1−] shuttle plasmid (for rapid
mobilization of genes into the larger HAdV-4 genome), the
portion of the Ad Type 4 genome spanning HAdV-4-nucleo-
tides #3085–#5978 nucleotides was additionally inserted intoHAdV-4-pShuttle. This region was PCR amplified from HAdV-4




specifically tailed primers incorporate a 5′-BclI and 3′-HindIII
recognition sites into the 5′ and 3′ ends of the PCR products
derived from use of these primers. The resultant ∼2900 bp
fragment was digested using BclI and HindIII and directionally
ligated into the HAdV-4 pShuttle (previously digested with BglII
and HindIII). Restriction digests as well as multiple sequencing
reactions confirmed the sequence identity and correct orientation
of the resulting clones, denoted as pHAdV-4[E1−] Shuttle (see
Supplementary Fig. 1). Once pHAdV-4[E1−] shuttle was gene-
rated, it was linearized by digestion with NruI, and co-trans-
formed into electro-competent BJ5183 bacterial cells along
with the I-SceI digested pHAdV-4 plasmid to generate p[E1−]
HAdV-4 genomic plasmids, a HAdV-4 containing plasmid
deleted for the E1 genes of HAdV-4, specifically nucleotides
#475–#3085.
To produce HAdV-4 based vectors that were also E3 deleted
(to effectively increase carrying capacity of the HAdV-4 vector
system further)we next created aHAdV-4E3 shuttling system. To
generate this, we PCR amplified the two HAdV-4 E3 “adjacent”
regions of HAdV-4 flanked with specifically indicated restriction
enzyme sites (nt. 25,810-28,366; and nt 30,575-34,536) using the





These fragments were then respectively digested using EcoRI
and HindIII, and ligated into a pUC19 plasmid that had been
similarly digested. Restriction digests and sequencing con-
firmed the correct sequence and orientation of the resulting
clone, pHAdV-4-E3. The pHAdV-4-E3 shuttle was co-trans-
formed with NdeI linearized p[E1−] HAdV-4 genomic
plasmids into BJ5183 cells, and kanamycin-resistant clones
were isolated and restriction enzyme mapped to confirm gene-
ration of p[E1−,E3−]HAdV-4 genomic plasmids (full cloning
and mapping details available upon request). After successful
recombination, all [E1−,±E3−] HAdV-4vector plasmids were
transferred to Stbl2 E. coli cells to permit high levels of plasmid
growth without vector recombination.
HAdV-4 vector construction and Ad vector purification
Briefly, a CMV-driven bacterial β-galactosidase gene (LacZ)
was subcloned into the pHAdV-4[E3−]shuttle plasmid (via XhoI
restriction site) and the pHAdV-4[E3−] CMV-LacZ shuttle plas-
mid was co-transformed into BJ5183 cells with NdeI linearized
pHAdV-4[E1−] to generate p[E1−,E3−]HAdV-4-CMV-LacZ.
The p[E1−,E3−]HAdV-4-CMV-LacZ plasmid was linearized
with I-SceI to release the HAdV-4-ITR's from the bacterial origin
and kanamycin resistance portions of the plasmid, and CaPO4
transfected into human 293 cells (containing Ad5 derived E1
region). Viral CPEwas noted, and the resultant [E1−,E3−]HAdV-
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numbers of 293 cells. After the respective vectors were grown to
high titers, concentration and purification of the vectors was
performed using a previously described cesium chloride double-
banding method (Amalfitano et al., 1998). All resultant Ad vector
stocks were evaluated for the presence of replication-competent
Ad (RCA) via a polymerase chain reaction (PCR)-based RCA
assay, essentially as described by Lochmuller et al. (1994).
Briefly, DNA isolated from the respective Ad vector preparations
was subjected to PCR using primers located within the E1 region
of both serotypes. Known quantities of Ad2 wild-type genome
(Invitrogen, Carlsbad, CA) or purified HAdV-4 DNA (RI-67
strain, ATCC) were used as positive controls for the respective
vector preparations. The RCA assay confirmed that the viral
preparations lacked significant amounts of replication- competent
(E1+) viral genomes, based on the sensitivity of the RCA assay
being able to detect at least 7.8×104 [E1+] Ad genomes in a
sample containing 2.75-3×1010 vector particles (data not shown).
To ensure that samples were not LPS-contaminated, purified
vectors were tested using an E-Toxate kit (Sigma, St. Louis,
Missouri) per manufacturers' recommendations with all preps
containing b0.01 EU per viral injection dose. Finally, vector
preparations were evaluated for potential differences in total
protein content using a Pierce (Rockford, IL) Bicinchoninic Acid
(BCA) Assay using the manufacturer's recommendations to
evaluate the total viral protein content for the respective vectors
using published literature. Both HAdV-4 and HAdV-5 vectors
(and wild-type counterparts) were found to have similar protein
content per equivalent numbers of viral particles.
In vitro assays
All cell lines were obtained from the American Tissue
Culture Collection (ATCC) and cultured according to suggested
guidelines. Viral infectivity was assessed by plating cells in 6
well dishes at concentrations of 4×105 cells per well. LacZ
transducing units were quantified on all cell types 24 h post-
infection using 2–6 fold log dilutions of vector in medium, as
previously described (Amalfitano et al., 1998). Additionally, a
quantitative assessment of LacZ transduction capability was
also obtained through a whole cell harvest of replicate wells
through use of a Beta-Galactosidase Activity kit (Stratagene, La
Jolla, CA) as per manufacturer's recommendations. UV
inactivation was performed using a ∼400 mW/cm2 UV dose,
shown to yield more than a 6-log10 inactivation of Ads (Gerba
et al., 2002; Hartman et al., 2006), and confirmed by separate
infectivity assays (data not shown). Heat treatment consisted of
placing Ad samples in a 56 °Cwater bath for 10min to dissociate
the penton-fiber from the capsid as has been previously shown
(Russell et al., 1967; Rexroad et al., 2003). All vectors
undergoing heat treatment were found to have lost over ∼5
logs of infectivity on 293 cells, assessed by visualization of LacZ
transduction. Equal OD260 particle numbers (determined as
previously described, (Maizel et al., 1968a,b)) of [E1−, E3, LacZ
+] purified HAdV-4 or HAdV-5 based vectors were used to
infect wells containing indicated cell types. Transfection
experiments were carried out using 1.5 μg of vector DNAextracted from viral preparations per 1 million RAW264.7 cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer's recommendations. Overlying medium
from the infected cells was harvested at indicated time points and
assessed using ELISA.
Culturing of human dendritic cells
Human dendritic cells were prepared essentially as described
inMorse et al. Briefly, peripheral blood monocytes from healthy
donors were thawed and allowed to adhere to a plate in serum-
free AIM-V media (Invitrogen, Carlsbad, CA). After 2 h,
the plate was gently washed with PBS and adherent mono-
cytes were cultured in AIM-V supplemented with GM-CSF
(800 U/ml) and IL-4 (500 U/ml; R&D Systems, Minneapolis,
MN). After culturing in this media for 5 days, cells were
assessed by FACS for HLA-DR and CD45 expression then
infected using 50,000 vp/cell of HAdV-4 or HAdV-5 based
vectors or mock infected.
Animal procedures
Adult C57BL/6 mice and B6.129S4-C3tmlCrr mice back-
crossed with C57BL/6 mice were purchased from Jackson Labo-
ratory (Bar Harbor, ME) and bred as previously described (Kiang
et al., 2006b; Wessels et al., 1995). Virus treatment of animals
(3–4 months in age) consisted of intravenous injection (via the
retro-orbital sinus) of 200 μl of a phosphate-buffered saline
solution (PBS, pH 7.4) containing virus particles of the respective
AdV-LacZ serotype 4 or 5 based vectors. Plasma and liver
samples were subsequently obtained and processed at the indi-
cated times post-injection using procedures approved by theDuke
University (Durham, NC) Institutional Animal Care and Use
Committee.
Assessment of viral transduction in vivo
Sections of snap frozen liver tissue embedded in Optimal
Cutting Temperature (OCT) fluid was sectioned at 7 μm and
then stained in situ for LacZ expression using X-Gal substrate
as previously described (Everett et al., 2004; Hartman et al.,
2007; Kiang et al., 2006b,a). To also quantitatively assess
overall LacZ activity, snap frozen samples were homogenized
and LacZ activity quantified using a β-Galactosidase Activity
kit (Stratagene, La Jolla, CA) as previously described (Kiang
et al., 2006b).
Ad genome copy number per cell
To assess the number of Ad genome copies per cell, tissues
were snap frozen in liquid nitrogen and then homogenized using
a mortar and pestle. After homogenization, DNAwas extracted
using a Gentra DNA Extraction kit (Gentra Systems, Minnea-
polis, MN) and copy numbers assessed using Real-Time PCR
based quantification. PCR reactions were performed on an ABI
7900HT Fast Real-Time PCR System using the SYBR Green
PCR Mastermix (Applied Biosystems, Foster City, CA).
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GTACCAACAGAGGA-3′, and reverse, 5′-AGATGCTTCA-
ACAGCACGTC -3′ and primers used to detect HAdV-4 were
5′-GACTCGTTCCTGGTCCAGAT-3′ and 5′- GTTAACCT-
CGTCCACCACCT-3′. Both vectors were also assessed using
CMV promoter specific primers: 5′- ACGCCAATAGGGA-
CTTTCCATTGAC-3′ and 5′- AGGGGGCGTACTTGGCA-
TATGATAC-3′. As an internal control for insuring adequate
DNA amplification, cellular DNAwas quantified using primers
spanning a region of GAPDH sequence (forward, 5′-AGAA-
CATCATCCCTGCATCC-3′, and reverse, 5′-CACATTGGG-
GGTAGGAACAC-3′). All PCRs were subjected to the
following procedure: 95.0 °C for 10 min followed by 40 cycles
of 95.0 °C for 15 s followed by 60.0 °C for 1 min. Standard
curves were run in duplicate and consisted of 6 half-log dilu-
tions using total genomic DNA or either HAdV-5- or HAdV-4-
[E1−]AdLacZ extracted DNA. These standard curves were used
to determine the number of viral genomes present per cell from
each sample. Melting curve analysis confirmed the quality and
specificity of the PCR.
ELISA and platelet measurements
To characterize Ad impact on systemic inflammation, a panel
of cytokines was investigated using a multi-plexed Enzyme
Linked Absorbance Assay (ELISA) based system, as previously
described (Hartman et al., 2007). Serum samples harvested at 0,
1, 6, and 24 h post-infection as well as tissue culture super-
natants were analyzed using a Luminex Array reader and the
Bio-Rad, BioPlex Murine Cytokine 23-plex kit or BioPlex
Human 27-plex kit according to the manufacturer's recommen-
dations. Interferon-β measurements were performed using a
PBL Interferon-β ELISA kit (Piscataway, NJ) according to the
manufacturer's recommendations. Statistically significant dif-
ferences for ELISA were determined using a two-tailed homo-
scedastic Student's t-test.
Platelet enumeration
o assess Ad vector induced thrombocytopenia, platelets were
measured at the given time points by retro-orbital blood draws
using the Unopette (Fisher-Scientific) system as previously
described (Kiang et al., 2006b). As per manufacture's
recommendations, platelets were counted using a Neubauer
hemocytometer and platelet levels were ascertained from these
counts. Statistically significant differences for platelet measure-
ments were determined using a two-tailed homoscedastic Stu-
dent's t-test.
Adenovirus antibody ELISA and LacZ ELISpot
To assess differential vector effects on the adaptive immune
response, mice were injected with 5×1010 particles of either
HAdV-4 or HAdV-5 LacZ bearing adenovirus via the footpad
and sacrificed 14 days after injection. To quantify murine anti-
adenovirus antibodies, a previously described ELISA method
was used (Michou et al., 1997). Briefly, 1×109 adenovirusparticles per well were bound to a 96 well plate in a bicarbonate
solution (200 mm NaHCO3, 81 mm Na2CO3, pH 9.5) at 4 °C
overnight. Wells were washed three times (PBS with .05%
Tween 20) and blocked for an hour at room temperature using a
2% bovine serum albumin (BSA) in PBS solution, rinsed in
PBS, and incubated with serum (at indicated dilution) for 60 min
at 37 °C. Wells were repeatedly washed with 400 μl of wash
buffer after which, 100 μl per well of a 1:2500 dilution of sheep
anti-mouse IgG or IgEH+L antibody (Jackson Immunoresearch
Laboratories) was added and allowed to incubate for 60 min at
37 °C. Finally, 100 μl per well of OPD substrate solution was
added to each well and allowed to incubate for 20 min. Absor-
bance was measured at 405 nm.
To quantify alloantigen-primed IFN-γ-producing T-cells,
an Enzyme Linked Immuno-Spot (ELISpot) assay was used,
essentially as described previously (Hobeika et al., 2005; Clay
et al., 2001; Maecker et al., 2005; Morse et al., 2005).
Multiscreen-HA 96-well plates (Millipore, Bedford, MA) were
coated overnight with capture anti-IFN-γ antibody (AN 18, at
1 mg/ml), washed five times with PBS, and then blocked for
2 h with RPMI1640-25mM HEPES-10%FBS at 37 °C.
Capture and detection anti-IFN-γ monoclonal antibodies
were purchased from MABtech USA (Mariemont, OH).
Donor splenocytes (5×105) were added to each well followed
by addition of PMA+Ionomicin (0.263 μg and 2.1 μg per well
respectively), LacZ protein (100 μg/ml, Sigma-Aldrich, St.
Louis, MO), Amyloglucosidase protein (100 μg/ml, Sigma-
Aldrich, St. Louis, MO), or media alone. Plates were incubated
for 24 h at 37 °C, then washed five times with PBS.
Biotinylated detection anti-IFN-γ antibody (R4-6A2; at
1 mg/ml) was then added at a 1:1000 concentration in PBS
+1%BSA and allowed to incubate for 2 h at room temperature.
Plates were then washed five times with PBS, after which,
100 μl of HRP-conjugated strepavidin (1/1000 dilution;
MABtech USA, Mariemont, OH) was added to each well for
60 min at room temperature. Plates were again washed five
times with PBS, developed with 3-amino-9-ethyl-carbazole
[AEC] (Sigma-Aldrich, St. Louis, MO), reconstituted in
acetate buffer for 4 min in the dark, washed with H2O, and
air dried. Membranes were attached to sealing tape (Millipore,
Bedford, MA) and the number of spots per well was deter-
mined using a KS ELISpot Automated Reader System with KS
ELISpot 4.2 Software (Carl Zeiss, Inc., Thornwood, NY).
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